根据吉林证监局出具的《关于对迪瑞医疗科技股份有限公司采取责令改正措施并对王学敏、牛丹丹、张 兴艳采取出具警示函措施的决定》（吉证监决〔2026〕4号），经核查发现，迪瑞医疗主要存在两方面 违规问题。 其一，公司涉外销售订单收入确认不审慎。公司2023年存在部分涉外销售订单确认收入后，对应商品未 实际报关并办理退货情形。上述行为导致公司2023年多记营业收入369.30万元，多记营业利润71.60万 元。 登录新浪财经APP 搜索【信披】查看更多考评等级 来源：环球网 【环球网综合报道】2月5日，迪瑞医疗科技股份有限公司（以下简称"迪瑞医疗"）发布公告称，当日收 到中国证券监督管理委员会吉林监管局（以下简称"吉林证监局"）出具的行政监管措施决定书，因公司 存在涉外销售订单收入确认不审慎、内部控制不完善等问题，被采取责令改正措施，3名相关责任人被 出具警示函。 其二，公司涉外销售内部控制不完善，部分涉外销售订单相关资料保存不完整。 上述行为致使迪瑞医疗2023年多记营业收入369.3万元，占其2023年营业收入的0.27%。 公开资料显示，迪瑞医疗主营业务为医疗检验仪器及配套试纸试剂的研发、生产、营销与服务，20 ...

公司磁导航消融导管及星型高密度标测导管获欧盟MDR认证，不仅助力公司进入欧洲市场，依托高附 加值产品进一步扩大海外收入规模，还完善了公司海外"标测+消融"技术矩阵，与现有三维标测系统形 成完整解决方案，强化了全能量消融技术壁垒，同时凭借精准、高效、安全的产品特性提升客户粘性、 夯实全球化品牌认知，为产品快速出海奠定了坚实基础。 格隆汇2月9日丨微电生理(688351.SH)公布，公司磁导航消融导管及星型高密度标测导管于近日获得了 欧盟医疗器械法规(The Medical DeviceRegulations (EU) 2017/745，以下简称"MDR")认证证书。 ...

赛科希德（688338.SH）2月9日在投资者互动平台表示，近年来公司高度重视海外业务发展，业务范围 已经拓展到俄罗斯、中东、南美等国家和地区。海外业务在公司整体业务中占比不高，目前处于发展和 增长的阶段。具体情况请关注公司后续披露的2025年年度报告。 每经AI快讯，有投资者在投资者互动平台提问：海外收入下半年与上半年有哪些突破，占比提升多 少？ （文章来源：每日经济新闻） ...

Core Viewpoint - Microelectrophysiology has received EU MDR certification for its magnetic navigation ablation catheter and star-shaped high-density mapping catheter, which will facilitate entry into the European market and expand overseas revenue [1] Group 1: Product Certification - The company announced that its magnetic navigation ablation catheter and star-shaped high-density mapping catheter have obtained EU MDR certification [1] - This certification is expected to enhance the company's overseas "mapping + ablation" technology matrix [1] Group 2: Market Impact - The entry into the European market is anticipated to increase the company's overseas revenue scale [1] - However, sales in international markets may be affected by uncertainties such as foreign regulatory policies, market environment changes, and exchange rate fluctuations [1] - The company is currently unable to predict the specific impact of these factors on its future business [1]

格隆汇2月9日｜微电生理公告，公司磁导航消融导管及星型高密度标测导管于近日获得了欧盟医疗器械 法规（TheMedicalDevice Regulations (EU) 2017/745，简称"MDR"）认证证书。 ...

Core Viewpoint - The market is experiencing a shift from a "style betting" approach to a "structural competition" approach, indicating a more nuanced investment landscape where various asset classes coexist simultaneously [6][26]. Group 1: Market Dynamics - Since the beginning of 2026, the market has shown significant volatility with rapid shifts in sentiment, leading to a perception of a lack of clear direction [1]. - Observing ETF-level capital flows reveals that the market is accommodating multiple directions rather than lacking direction [2]. - A notable change is occurring in the aesthetic of capital, suggesting a stratification in investment preferences [3][4]. Group 2: Technology Sector Insights - The A+H technology sector is emerging as a focal point in the current structural layering of the market [8]. - Historically, technology assets were viewed as temporary trading tools rather than structural assets, with narratives shifting between growth potential and risk concerns [9][10]. - As of 2025, the understanding of technology is evolving to focus on its role within the industrial structure rather than just valuation [12][13]. Group 3: Hong Kong Stock Market Developments - The narrative surrounding Hong Kong technology stocks is shifting from "repair" to "technological transformation," reflecting a more balanced understanding of their role in the global market [14][15]. - The Guozhen Hong Kong Stock Connect Technology Index emphasizes a balanced approach, focusing on companies with stable growth and R&D investment across various sectors [16][19]. Group 4: Artificial Intelligence and Future Trends - The market's perception of artificial intelligence is evolving from a conceptual level to a more structured understanding of its industry chain positioning [20]. - The Zhongzheng Innovation and Entrepreneurship AI Index represents a comprehensive view of the AI industry, covering various layers from infrastructure to applications [23][24]. Group 5: Stability and Structural Evolution - The market is forming a multi-layered structure where technology assets represent high growth potential, while stable cash flow assets serve as stabilizers [25]. - The Zhongzheng Hong Kong Stock Connect High Dividend Select Index introduces a quality screening mechanism, focusing on companies with strong dividend attributes and structural integrity [25]. - The overall trend indicates a shift towards a more structured investment approach, reflecting the maturation of capital and the integration of the Chinese capital market into the global system [26][27].

Core Viewpoint - The company, Kehua Bio-engineering, disclosed its construction in progress balance as of June 30, 2025, amounting to 1,640,045.17 yuan, which includes renovation and miscellaneous projects [1]. Group 1 - The company responded to investor inquiries on its interactive platform regarding its financial status [1]. - The balance of construction in progress is detailed in the company's semi-annual report for 2025 [1].

特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 近日， 新发突发与重大传染病防控 国家科技重大专项 "乙肝病毒多场景多元快速检测技术研发与应用"（项目编号： 2025ZD01906800 ） 项目启动会在北京医院召开 。项目相关领导、项目学术委员会专家、项目组成员等共同参与此次会议，围绕项目的技术路线、创新点与实施计 划等展开讨论。 新发突发与重大传染病防控国家科技重大专项遵循《"健康中国2030"规划纲要》《"十四五"国民健康规划》，旨在聚焦传染病防控领域的关 键技术难题，提升国家传染病防控能力。此次开展的项目由 北京医院（国家卫生健康委临床检验中心）王露楠教授担任项目负责人 ，联合四 川大学华西医院、南方医科大学南方医院、天隆科技等多家国内顶尖科研机构、临床医院及产业单位协同攻关。天隆科技凭借在传染病检测领 域的技术积淀与行业影响力，成为该项目中子课题 "高敏便携式HBV DNA即时检测关键技术研究与系统研制" 的牵头承担单位，全力推进乙 肝快速检测相关技术的研发与落地应用。 我 国 乙 肝 病 毒 （ HBV ） 感 染 人 群 基 ...

Core Insights - In 2025, a total of 10 flow cytometers received NMPA certification, with 9 being domestic brands, indicating a trend towards high-end, intelligent, and multi-parameter technology that supports clinical precision medicine [1][30]. Group 1: Industry Overview - Flow cytometry, developed in the 1970s, has evolved from basic research to clinical applications in disease diagnosis and treatment monitoring, with the first flow cytometer introduced in China in the early 1980s [2]. - Flow cytometers can measure cell size, internal particle characteristics, and detect surface and cytoplasmic antigens, as well as DNA and RNA content, allowing for rapid analysis of large cell populations [2]. Group 2: Certification and Product Highlights - In 2025, 10 flow cytometers were approved, including 9 domestic brands and 1 imported brand, with notable models such as Cl inStel lar AX from Chenglang Bio, which received certification in December [3][6]. - The Cl inStel lar AX is a high-end spectral flow cytometer that breaks the monopoly of imported brands in the high-end clinical field, providing cost-effective solutions for domestic medical institutions [6][30]. - The BioCy teX from Zhongsheng Medical is the first domestic 4-laser 21-color flow cytometer, marking a significant breakthrough in high-end flow cytometry capabilities [15][30]. Group 3: Technological Advancements - Prism Tech has achieved breakthroughs in PMT and APD detector technologies, creating a dual-platform system that enhances the technical breadth and application depth of domestic flow cytometers [7][30]. - Automation and intelligence upgrades are evident in devices like the Khroma series from Meiruite and EasyCell Plus from Weigong Technology, which feature high-throughput automatic sample loading systems [10][19][30]. Group 4: Market Trends and Future Outlook - The rapid increase in domestic brand certifications indicates a shift towards domestic alternatives and internationalization, with Zhongsheng Medical's BioCy te gaining registration in Indonesia, marking the beginning of overseas expansion for domestic manufacturers [31]. - The flow cytometry market is moving towards automation, intelligence, and multi-dimensional development, expanding applications from hematology to oncology, cell therapy, and infectious immunity [31].

Group 1 - The core point of the article is that the company, CaiNa Technology Co., Ltd., has received a patent for a "backflow prevention blood collection needle" from the National Intellectual Property Administration of China [1] - The patent was granted to Jiangsu CaiNa Medical Technology Co., Ltd., a wholly-owned subsidiary of CaiNa Technology [1] Group 2 - The article also highlights the trend of young executives, specifically those born in the 2000s, taking on significant roles in A-share companies, which poses a challenge to meet investor expectations [1] - A specific example mentioned is a 26-year-old who has recently returned from studying at a prestigious American university and has assumed the roles of chairman and general manager [1]